Dear Nearly Done....Who are you?A Stockhouse member since August 4, 2016. Two days after I read the real disconcerting press release from Telesta that took TST to a low of 3.5 cents. The "x factor" you mention is NOT as nearly done as you assume. And, rolling over for 14 cents. Bottomline, I am extremely disappointed in the depth/detail/background of information from Telesta since the FDA decision. From Ipsen returning MCNA rights to Telesta, to non-asset value MCNA surprise (but good to return anyways?), to the up to $50 mil in potential tax attributes (and their potential value). BTW, thank you ProMetics for first mentioning the latter in your press release. Hence, I assume the worse, as a long-standing shareholder of Bioniche/Telesta. We need an Advocate that will listen to any of us without fee$. And, one that carries a BIG STICK. That Advocate of "Minority Shareholders" is the OSC. I've recently written to the OSC detailing my concerns as stated above. They have responded that they will review (see email below). However, "Strength is in Numbers". And, likely very helpful, supportive if any other upset TST shareholders write to the OSC. Takes the same amount of time to write an email to the OSC as it took Scroll the time to summarize her/his concerns in a recent post. The one thing to keep in mind, the OSC is focused on proper disclosure. They will not comment on the value of the deal. They made that loud and clear to me. If upset, YOU have the opportunity to act. Thank you to all that do. rg Sharing my response from the OSC.... From: On Behalf Of inquiries@osc.gov.on.ca Sent: September-08-16 4:35 PM To: rg Subject: Re: Telesta Therapeutics Inc. Dear xx: Thank you for your follow up email to the Ontario Securities Commission (OSC) concerning disclosure made by Telesta Therapeutics Inc. I have forwarded the information you provided to the Corporate Finance branch of the OSC for further review. Their review of this matter will focus on any potential violation of Ontario securities law, and in particular disclosure related concerns. Please note that regulatory reviews, and any subsequent investigation, are conducted privately. Any issues that staff may identify will be addressed with the issuer directly. Sincerely, XX Ontario Securities Commission inquiries@osc.gov.on.ca 416-593-8314 1-877-785-1555